Search for a command to run...
Regulation on Products Derived from Human Tissues and Cells (Official Gazette 04.09.2025, No. 33007): A Hard-Edged Compliance Guide for Clinics, Bioba
No comments yet. Be the first to comment.
Online Eğitim ve Zoom Gelirlerinde %15 Vergi: 2026 Tarihli 20/B Özelgesi
Türkiye’de Yaşayanların Yurt Dışı Airbnb Geliri Nasıl Vergilendirilir?
Sosyal Medya ve Dijital Gelirlerde Vergi İstisnası: 2026 Tarihli Yeni Özelge 20/B’nin Sınırlarını Netleştirdi
2026 Birden Fazla İşverenden Ücret Alanlar: 400.000 TL ve 5.300.000 TL Beyan Sınırı
Türkiye’den İtalya’ya Taşınanlar İçin Vergi Planlaması: Yabancı Hisse Senetleri, ABD Borsası ve Sermaye Kazançları
Meta title: Human Tissue and Cell Regulation 2026 – Who Is Affected and What Needs to Be Done?
Slug: human-tissue-cell-regulation-2026-compliance-guide
Meta description: The new Regulation on Products Derived from Human Tissues and Cells and Related Centers, effective January 1, 2026. Coverage, license types, quality/traceability, biobank obligations, prohibitions, and sanctions. A step-by-step compliance roadmap for hospitals, biobanks, and ATMP manufacturers.
Straight talk: This is not a “nice overview.” It’s a direct to-do list. The Regulation imposes heavy data retention, traceability, and quality obligations. It takes effect on January 1, 2026. Existing facilities have a one-year transition window. Failure to comply can result in suspension or cancellation of licenses and even closure.
The section headings are based on actual Google queries. Each section answers one question in depth. At the end, you’ll find FAQ schema and a CTA.
Purpose: To regulate fair access, quality, and safety standards for human tissue/cell–derived products and to define licensing, infrastructure, staffing, and oversight for centers active in this field.
Scope (summary):
The entire chain: procurement, testing, processing, preservation, storage, distribution, disposal, transport, and clinical application.
Imports/exports, monitoring systems, and experimental or clinical trials.
Biobanking: collection, storage, processing, and sharing of human biological materials and related data.
Exclusions:
Licensing of bone marrow transplant centers (the transplant act itself is covered).
Blood banking and plasma fractionation.
Assisted reproductive (IVF/ART) centers.
Organ/composite tissue transplants.
Non-human (animal, plant, synthetic) sources.
Human tissues/cells collected solely for scientific research, not clinical use.
Medical devices regulated under separate legislation.
Effective date: January 1, 2026.
Transition: Existing centers must comply within 1 year.
Repealed: 2005 Cord Blood Banking Regulation and the 2010 Tissue/Cell Quality and Safety Regulation.
General Directorate of Health Services (SHGM)
Turkish Medicines and Medical Devices Agency (TİTCK)
TÜSEB
Additionally:
Tissue and Cell Coordination Commission: strategic, chaired by the deputy minister.
Scientific advisory committees: technical opinions.
Tissue and Cell Procurement Centers
Handle autologous/allogeneic procurement.
Must ensure donor consent, medical suitability, and records (30 years minimum).
Tissue and Cell Centers
Licensed for procurement, processing/production, or storage/distribution (one or multiple).
Processing/production centers: must comply with GMP/GTP/GLP; final release criteria; expiry dates.
Storage/distribution centers: responsible for safety during storage, import/export, and pre-clinical checks.
Clinical Application Centers
Apply licensed tissues/cells and Advanced Therapy Medicinal Products (ATMPs).
Must report adverse events/effects back to the supplying center.
Note: Centers may only operate with TİTCK-approved products, methods, and categories.
Pre-approval: File to provincial health authority with project, staff, funding, and requested license type. Must convert to full license within 1 year.
Full license application: Requires staff list, qualifications, SOPs, quality manual, equipment validation, IT security, insurance, service contracts, and GMP/GTP compliance.
Inactive licenses: If no activity within 6 months, the license is revoked.
Quality Management System (QMS): SOPs, risk management, CAPA, internal audits, change control, recall systems.
Infrastructure: controlled clean rooms, validated HVAC, contamination prevention.
Equipment: annual calibration, IQ/OQ/PQ validations.
Materials: supplier audits, critical consumables certification.
Continuity: disaster recovery, backup equipment, tested annually.
SEC (Single European Code): mandatory coding and labeling.
Traceability: minimum 30 years of post-clinical application record retention.
Retained samples: at least 2 years.
QMS records: at least 10 years.
Critical: Products without SEC traceability cannot be distributed or applied clinically.
Biobanks: Require TİTCK licensing, strong data protection, and access controls.
ATMPs: A product is ATMP if it involves substantial manipulation, systemic effect, or non-homologous use.
Unlicensed ATMPs cannot be transferred/applied outside clinical trials.
Unauthorized activity: immediate suspension and referral to prosecutors.
Misleading advertising/hope marketing: strictly prohibited.
Financial incentives for donors: forbidden (except necessary expenses).
Commercialization of human tissues/cells: banned.
Inspections: at least annually. Noncompliance = suspension/cancellation.
National reserve: emergency stock for disasters.
Import/export: only by licensed storage/distribution centers.
National biovigilance system: monitors adverse reactions nationwide.
| Institution/Actor | Impact | Key Burden |
| Hospitals & universities | High | Licensing, SEC traceability, adverse event reporting |
| Biobanks | Very High | Licensing, data security, 30-year record retention |
| ATMP manufacturers | Very High | GMP/GTP/GLP, validation, release criteria |
| Procurement centers | High | Donor consent, medical suitability SOPs |
| Clinical research hospitals | High | Clinical trial compliance, ethics approval |
| Logistics providers | Medium-High | Cold chain validation, labeling traceability |
| Labs (authorized testing) | Medium | Validation, reporting integrity |
First 30 days:
Map current activities.
Conduct gap analysis (SEC, records, validation, QMS).
Appoint responsible persons (Medical, QMS, QC, Biovigilance, etc.).
Within 90 days:
Draft SOPs.
Set up SEC labeling.
Validate critical equipment.
Secure liability insurance.
Within 180 days:
Conduct internal audit and CAPA cycle.
Test business continuity.
Audit suppliers.
By day 365:
Submit complete licensing file.
Finish staff training.
Activate biovigilance reporting.
No. Only reimbursement of necessary expenses.
No. Only within clinical trials.
30 years post-application; 10 years for QMS docs; 2 years for retained samples.
Yes. Products without SEC cannot be distributed or applied.
No. Misleading or promotional statements are banned.
Organizational chart & job descriptions
Qualified responsible persons with credentials
Quality manual, SOP list, SEC labels
HVAC validation, clean room certification
Critical consumables audit trail
IT/data security documentation
Liability insurance
Supplier/third-party contracts
Recall procedures
Continuity/disaster recovery plan
Staff training records
Product recalls (with documentation kept 30 years).
Destruction/quarantine of non-compliant products.
Suspension/cancellation of activity licenses.
Direct ministry intervention if recalls are mishandled.
Pick your scope carefully (procurement vs processing vs storage).
Build SEC and traceability systems early.
Treat validation as integral, not paperwork.
Keep a tight leash on third-party contracts—you remain liable.
Avoid even the appearance of “hope marketing.”
If you’re running a hospital, biobank, or ATMP manufacturing line, you’ll need a premium compliance project: licensing strategy, GMP/GTP quality architecture, SEC labeling, validation, audits, and submission files.
Reach out for:
30-day gap analysis
Licensing strategy & capacity planning
QMS/SOP package & SEC system
Validation master plan (IQ/OQ/PQ)
Internal audit & CAPA cycle
Licensing file preparation & inspection coaching
Contact us: We’ll pre-screen your current setup with a 15-point compliance checklist and provide a tailored proposal.
Would you like me to also prepare a condensed 1,200-word “executive briefing” version of this in English (for board-level presentations), or do you prefer to keep the full 3,000-word compliance blog format?
